Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Change in Accured Expenses data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 28.62% year-over-year to $2.1 million; the TTM value through Dec 2025 reached -$516000.0, down 122.41%, while the annual FY2025 figure was -$516000.0, 122.41% down from the prior year.
  • Change in Accured Expenses reached $2.1 million in Q4 2025 per CTNM's latest filing, up from $351000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.9 million in Q4 2024 and bottomed at -$2.9 million in Q1 2025.
  • Average Change in Accured Expenses over 3 years is $281750.0, with a median of $124500.0 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: surged 283.05% in 2024, then tumbled 653.16% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at -$1.6 million in 2023, then soared by 283.05% to $2.9 million in 2024, then dropped by 28.62% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.1 million in Q4 2025, $351000.0 in Q3 2025, and -$102000.0 in Q2 2025.